- Details
- Description
LUCICAPMA 200 mg (Capmatinib) is a targeted anticancer medicine containing capmatinib, a selective inhibitor of the MET receptor tyrosine kinase. Capmatinib is designed to inhibit abnormal MET signaling, including signaling associated with specific alterations in the MET gene that can contribute to the growth and spread of cancer cells.
Capmatinib is used for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific MET alterations, including MET exon 14 skipping alterations, as determined by an appropriate diagnostic test.
LUCICAPMA 200 mg is an oral medicine intended for use under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, monitoring, and management of potential adverse reactions or drug interactions should be determined according to official prescribing information and the individual patient's clinical condition.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals should consult the applicable official product information before prescribing or dispensing this medicine.
